

Supplementary Table S1. Primers used in PCR reaction to amplify the HLA region *B*51-01A* and *B*51-24A*.


Primer Mix ID	Allele specificity	Sense primer	Sense primer localisation	Antisense primer	Antisense primer localisation	Size of PCR product
<i>B51-01^a</i>	B*1807, B*3521/24, B*510101-0107/03-04/06/08-09/11N-14/16-21/24-33/35/37-39/41N/43-46, B*5302/06, B*7801-0202	CTT	272	CAC	583	590
<i>B51-24^a</i>	B*510101-0103/0105-09/11N-12/1302-14/16-23/26-41N/43-44N/46, B*520101-10, B*5808	TCC	319	AGA	435	345

HLA: human leukocyte antigen; ID: identification; PCR: polymerase chain reaction.


Supplementary Table S2. Disease manifestations in patients with Behçet's disease.

Disease manifestations	Results n= 83
Oral ulcers, n (%)	83 (100.0)
Genital ulcers, n (%)	67 (80.7)
Cutaneous involvement, n (%)	61 (73.5)
Eye inflammation, n (%)	55 (66.3)
Joint involvement, n (%)	30 (36.1)
Neuro-Behçet, n (%)	19 (22.9)
Positive patergy test, n (%)	11 (24.4)*
Vasculo-Behçet, n (%)	15 (18.1)
Gastrointestinal involvement, n (%)	4 (4.8)
Relapsing neuro-Behçet, n (%)	7 (8.4)
Relapsing vasculo-Behçet, n (%)	3 (3.6)

*The patergy test was performed in 45 patients; n: number of patients.

**Supplementary Fig. S1.** Image of PCR reaction products after electrophoretic run on 2% agarose gel.

The positive bands for the 590bp (B51-01A primer) and the 395bp (B51-04A primer) show the amplification of the area of interest. "M" is the 1Kb marker (Invitrogen by Life Technologies); "A1 to A5": samples from study's participants; "CN": negative control; "CP": positive control.



Supplementary Fig. S2. Representative figure of the analysis of HLA-B*51 sequencing using the software U-type.